Results 131 to 140 of about 11,456 (188)

SGLT2 Inhibitors: Dual Effects on Erythropoiesis and Bone Metabolism. [PDF]

J Bone Metab
Mohammad AH, Mohammad SH, Alsaaty MH.
europepmc   +1 more source

Effects of SGLT2 inhibitors on body composition and potential sarcopenia-related outcomes in type 2 diabetes mellitus: a network meta-analysis. [PDF]

Front Endocrinol (Lausanne)
Li X, Zhang Y, Wang L, Zhao Y.
europepmc   +1 more source

Canagliflozin Alleviates Diabetic Glomerular Endothelial Injury via Melibiose in a Microbiota-Dependent Manner. [PDF]

Adv Sci (Weinh)
Zhang W, Song Y, Li C, Luo Y, Shao M, Guo F, Wei F, Fan X, Guo W, Xu F, Sang Y, Zhang D, Zhou Y, Wang L, Kang Z, Yang Y, Song C, Liu Y, Ma X, Wang J, Li C, Ma S, Zhao L, Qin Z, Xing G, Zhao Q, Li J, Song S, Zhao D, Huang T, Wang Q, Zhao Y, Qin G.   +32 more
europepmc   +1 more source

Canagliflozin and Brusatol Synergize against LKB1-KEAP1 Co-Mutant NSCLC through AKT Suppression. [PDF]

Int J Biol Sci
Chen Y, Gao XZ, Rong D, Gao L, Tang M, Lu G, Ling ZQ, Shen HM.   +7 more
europepmc   +1 more source

Comparison of effectiveness and safety of bexagliflozin and other sodium-glucose cotransporter 2 inhibitors for type 2 diabetes mellitus in adults: systematic review and network meta-analysis of randomized controlled trials. [PDF]

Front Endocrinol (Lausanne)
Gao S, Zhang F, Xie X, Fan L.
europepmc   +1 more source

Comparative Effectiveness of Individual Sodium Glucose Transporter 2 Inhibitors on Cardiovascular Outcomes in Type 2 Diabetes With Moderate Cardiovascular Risk: Emulation of a Target Trial. [PDF]

J Am Heart Assoc
Zehra A, Deng Y, Swarna KS, Herrin J, Polley EC, Neumiller JJ, Galindo RJ, Umpierrez GE, Ross JS, Brito JP, Montori VM, Borah BJ, Maron BA, Mickelson MM, McCoy RG.   +14 more
europepmc   +1 more source

Canagliflozin attenuates Parkinson's disease and is associated with modulation of gut-inflammasome-brain axis in rats. [PDF]

Inflammopharmacology
Gamal NK, Fakhry R, Hatem Y, Rashed E, Marzouk R, Bukr AKM, Safwat K, Mamdouh M, AbdElFatah A, Atallah A, Attia H, Ayoub IM, George MY.   +12 more
europepmc   +1 more source

Reassessing the risk-modifying effects of novel antidiabetic agents on asthma-COPD overlap syndrome: a dose-stratified network meta-analysis of 316,832 adults from 128 randomised trials. [PDF]

EClinicalMedicine
Zeng BY, Hsu CW, Hung CM, Yang WC, Stubbs B, Chen YW, Lei WT, Chen JJ, Chen TY, Hsu SP, Wang HY, Shiue YL, Zeng BS, Li CT, Su KP, Liang CS, Suen MW, Tseng PT.   +17 more
europepmc   +1 more source

Comment on Hong et al. Differential Effect of GLP-1 Receptor Agonists and SGLT2 Inhibitors on Lower-Extremity Amputation Outcomes in Type 2 Diabetes: A Nationwide Retrospective Cohort Study. Diabetes Care 2025;48:1728-1736. [PDF]

Diabetes Care
García de Lucas MD, López Carmona MD.
europepmc   +1 more source

Sodium-glucose cotransporter-2 inhibitors and gastrointestinal neoplasm risk in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. [PDF]

Clin Exp Med
Zhang YF, Xie JJ, Wu Q, Zhou XY, Zeng C, Zeng Y, He YM, Guo M, Teng FY, Xu Y.   +9 more
europepmc   +1 more source